Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.

TitleImpact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
Publication TypeJournal Article
Year of Publication2016
AuthorsGanz PA, Petersen L, Bower JE, Crespi CM
JournalJ Clin Oncol
Date Published2016 Mar 10
KeywordsAntineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Cohort Studies, Female, Humans, Middle Aged, Mind-Body Relations, Metaphysical, Psychophysiology, Quality of Life, Self Report, Tamoxifen

PURPOSE: To examine patterns of health and symptoms associated with the initiation of adjuvant endocrine therapy (ET) for primary breast cancer treatment.

PATIENTS AND METHODS: The mind-body study (MBS) observational cohort participants provided self-reported data on physical and mental health, ET-related symptoms, as well as depression, fatigue, and sleep obtained at enrollment (after primary treatment, prior to initiation of ET) and 6 and 12 months later. Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models.

RESULTS: Two-thirds of the 186 women initiated ET, which was evenly split between AI and tamoxifen, and no significant differences were observed in self-reported measures among the groups at baseline or in covariate-adjusted analyses. Physical health scores were below normative levels initially and improved over time, but the AI group had a significantly lower score at 12 months (P = .05); mental health scores were within the normal range, were similar in each group, and did not change over time. The no-ET group showed either stable or declining symptom severity, whereas the ET groups often showed increased severity over time, and the AI group reported more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) at one or both of the follow-up time points compared with the no-ET group. The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), and bladder problems (P = .02) than the no-ET group.

CONCLUSION: Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes.

Alternate JournalJ. Clin. Oncol.
PubMed ID26786934
PubMed Central IDPMC4872009
Grant ListP30 CA16042 / CA / NCI NIH HHS / United States
R01 CA 109650 / CA / NCI NIH HHS / United States